- Home
- CFFN vs KZR Comparison
CFFN vs KZR Comparison
Compare CFFN & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFFN
- KZR
- Stock Information
- Founded
- CFFN 1893
- KZR 2015
- Country
- CFFN United States
- KZR United States
- Employees
- CFFN N/A
- KZR N/A
- Industry
- CFFN Savings Institutions
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CFFN Finance
- KZR Health Care
- Exchange
- CFFN Nasdaq
- KZR Nasdaq
- Market Cap
- CFFN 813.3M
- KZR 29.7M
- IPO Year
- CFFN 1999
- KZR 2018
- Fundamental
- Price
- CFFN $6.47
- KZR $3.81
- Analyst Decision
- CFFN Hold
- KZR Hold
- Analyst Count
- CFFN 1
- KZR 2
- Target Price
- CFFN $6.50
- KZR $9.00
- AVG Volume (30 Days)
- CFFN 609.6K
- KZR 30.5K
- Earning Date
- CFFN 10-22-2025
- KZR 11-11-2025
- Dividend Yield
- CFFN 5.36%
- KZR N/A
- EPS Growth
- CFFN N/A
- KZR N/A
- EPS
- CFFN 0.47
- KZR N/A
- Revenue
- CFFN $192,483,000.00
- KZR N/A
- Revenue This Year
- CFFN $10.56
- KZR N/A
- Revenue Next Year
- CFFN $11.73
- KZR N/A
- P/E Ratio
- CFFN $13.48
- KZR N/A
- Revenue Growth
- CFFN N/A
- KZR N/A
- 52 Week Low
- CFFN $4.90
- KZR $3.62
- 52 Week High
- CFFN $7.20
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- CFFN 56.49
- KZR 41.06
- Support Level
- CFFN $6.25
- KZR $3.76
- Resistance Level
- CFFN $6.51
- KZR $4.05
- Average True Range (ATR)
- CFFN 0.12
- KZR 0.14
- MACD
- CFFN -0.02
- KZR -0.01
- Stochastic Oscillator
- CFFN 58.11
- KZR 22.73
About CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.